Vivimed Labs Limited has announced that its Board of Directors will meet on February 13, 2026, to review and approve the company's third quarter financial results for FY26. The pharmaceutical company made this announcement in compliance with regulatory requirements, notifying both major stock exchanges about the scheduled board meeting.

Meeting Details and Agenda

The board meeting is scheduled to take place on Friday, February 13, 2026, at the company's Hyderabad office. The primary agenda includes consideration and approval of unaudited financial results covering both standalone and consolidated performance metrics.

Regulatory Compliance

The announcement was made pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements), 2015. Vivimed Labs communicated this information to both BSE Limited and National Stock Exchange of India Ltd, where the company's shares are traded under the codes BSE - 532660 and NSE - VIVIMEDLAB respectively.

Company Information

Vivimed Labs Limited operates with its registered office located at Kolhar Industrial Area, Bidar, Karnataka, while maintaining its corporate office in Hyderabad, Telangana. The company secretary Yugandhar Kopparthi signed the official communication to the stock exchanges. The meeting agenda also includes consideration of any other items that may be brought before the board during the session.

Investors and stakeholders will be awaiting the financial results that will provide insights into the company's performance for the quarter and nine months ending December 31, 2025.

Vivimed Labs Limited has received official confirmation from both BSE Limited and the National Stock Exchange of India Limited (NSE) regarding the revocation of trading suspension for its equity shares. The announcement marks a significant milestone for the pharmaceutical company and its shareholders who have awaited the resumption of trading activities.

Official Revocation Details

The stock exchanges issued their official communications on December 10, 2025, confirming the decision to lift the trading suspension. The revocation follows the company's successful compliance with regulatory requirements and addresses previous non-compliances under SEBI (LODR) Regulations, 2015.

Regulatory Framework and Compliance

The revocation operates under the provisions of SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. This master circular replaced the erstwhile SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, providing the regulatory framework for such revocations.

Vivimed Labs Limited has diligently worked to address all regulatory concerns and has committed to maintaining compliance standards going forward. The company expressed gratitude to both exchanges and shareholders for their support during the challenging compliance period.

Market Resumption Process

Trading in Vivimed Labs Limited equity shares will resume through a structured process designed to ensure orderly market reopening. The scrip will participate in the Special Pre-open Session for IPOs & Relisted Scrips on December 18, 2025, before regular trading commences.

This special session helps facilitate price discovery and provides market participants with an organized mechanism to resume trading activities. The company's shares will trade in the T group under the Trade for Trade category, which requires delivery-based settlements.

Company Commitment and Outlook

Vivimed Labs Limited has assured stakeholders of its continued commitment to regulatory compliance, transparency, and sustained shareholder value creation. The company views this revocation as a turning point that reinstates liquidity for shareholders and enables proper price discovery mechanisms.

The pharmaceutical company, with its registered office in Bidar, Karnataka, operates in the healthcare sector and has worked systematically to resolve compliance issues. With trading resumption imminent, the company looks forward to renewed market participation and continued business operations under proper regulatory oversight.